everlywell

27:I[56264,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js","/_next/static/chunks/2tie5rqwdsi89.js","/_next/static/chunks/2dnipz2c0692b.js","/_next/static/chunks/1mf5iq195c2sn.js","/_next/static/chunks/03wn0-bzh3abk.js","/_next/static/chunks/0_02m0ghanddv.js"],"GuestHistoryRecorder"] 28:I[3004,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js","/_next/static/chunks/2tie5rqwdsi89.js","/_next/static/chunks/2dnipz2c0692b.js","/_next/static/chunks/1mf5iq195c2sn.js","/_next/static/chunks/03wn0-bzh3abk.js","/_next/static/chunks/0_02m0ghanddv.js"],"EmailPreview"] 2b:I[27201,["/_next/static/chunks/3fntmmi971322.js","/_next/static/chunks/1ymt1shyhmu-4.js","/_next/static/chunks/291ciwmgtp_xc.js","/_next/static/chunks/2owa30hnifmhr.js"],"IconMark"] 29:Taf38, everlywell

How can one test screen for so many cancers?

It starts with your DNA — and your RNA.

Some multi-cancer early detection blood tests analyze one signal type: chemical patterns in your DNA (known as methylation) that shift when cancer develops.

Caris Detect™ is different.
It combines whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to analyze genome-wide DNA and RNA changes in your blood — evaluating multiple biological signals associated with cancer. Its proprietary AI, informed by more than 1 million profiled cases, helps identify signals that may otherwise go undetected.

Caris Detect looks across many cancer types, including those with standard screening guidelines and many others that currently have no routine screening test. Some signals may be detected as early as Stage I + II.²

The result: a broader, deeper look that can offer early insight before symptoms appear — helping inform next steps.

Learn more about Caris Detect →

Cancer Screening

Biomarker intelligence.
Real-world impact.

Shop

Everlywell 360

Learn

Refer a Friend

Contact

This email was sent by Everlywell

5209 Burnet Road, Suite 300, Austin, TX 78756

Can't see this email? View online.

Privacy Notice Terms of Use Unsubscribe

Caris Detect is a multi-cancer early detection laboratory-developed test performed in a CLIA-certified, CAP-accredited laboratory utilizing whole genome sequencing, whole transcriptome sequencing and advanced artificial intelligence. It is designed to detect early-stage cancer signals from cell-free DNA and cell-free RNA in the blood. Whole exome sequencing and whole transcriptome sequencing (Caris Assure®) are utilized for patients that receive a “Cancer Signal Detected” in order to provide the Suspected Tissue of Origin.

Your purchase may be HSA/FSA eligible. Check with your plan administrator. Everlywell is not responsible for contacting your plan administrator on your behalf.

Everlywell works with a network of licensed clinicians who review your request and order the test. Caris Detect™ Multi-Cancer Early Detection Test is performed by Caris Life Sciences' CLIA-certified, CAP-accredited laboratory. Results are provided to you and made available in your online portal.

Caris Detect does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results may occur. Caris Detect is intended to complement, not replace, recommended cancer screening tests and other medical evaluations, so it is important that you continue recommended cancer screenings and routine preventive healthcare based on your individual risk factors.

Results should be interpreted in conjunction with discussion with your healthcare provider and potential follow-up diagnostic testing. A positive result is not a diagnosis. A negative result does not rule out cancer or mean that an individual will not develop cancer in the future.

² Reference: Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, Yoshino T, Heath EI, Lou E, Liu SV, Marshall JL, El-Deiry WS, Shields AF, Dietrich MF, Nakamura Y, Fujisawa T, Demetri GD, Barker A, Xiu J, Sacchetti S, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert DD, Oberley M, Radovich M, Sledge GW, Spetzler DB. Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. Sci Rep. 2025 Jul 15;15(1):21173. doi: 10.1038/s41598-025-08986-0. PMID: 40596693; PMCID: PMC12214926.

2a:T13d6,everlywell Caris Detect goes deeper than most MCED tests. How can one test screen for so many cancers? It starts with your DNA — and your RNA. Some multi-cancer early detection blood tests analyze one signal type: chemical patterns in your DNA (known as methylation) that shift when cancer develops. Caris Detect™ is different. It combines whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to analyze genome-wide DNA and RNA changes in your blood — evaluating multiple biological signals associated with cancer. Its proprietary AI, informed by more than 1 million profiled cases, helps identify signals that may otherwise go undetected. Caris Detect looks across many cancer types, including those with standard screening guidelines and many others that currently have no routine screening test. Some signals may be detected as early as Stage I + II.² The result: a broader, deeper look that can offer early insight before symptoms appear — helping inform next steps. Learn more about Caris Detect → Cancer Screening Biomarker intelligence. Real-world impact. Shop Everlywell 360 Learn Refer a Friend Contact This email was sent by Everlywell 5209 Burnet Road, Suite 300, Austin, TX 78756 Can't see this email? View online . Privacy Notice Terms of Use Unsubscribe Caris Detect is a multi-cancer early detection laboratory-developed test performed in a CLIA-certified, CAP-accredited laboratory utilizing whole genome sequencing, whole transcriptome sequencing and advanced artificial intelligence. It is designed to detect early-stage cancer signals from cell-free DNA and cell-free RNA in the blood. Whole exome sequencing and whole transcriptome sequencing (Caris Assure®) are utilized for patients that receive a “Cancer Signal Detected” in order to provide the Suspected Tissue of Origin. Your purchase may be HSA/FSA eligible. Check with your plan administrator. Everlywell is not responsible for contacting your plan administrator on your behalf. Everlywell works with a network of licensed clinicians who review your request and order the test. Caris Detect™ Multi-Cancer Early Detection Test is performed by Caris Life Sciences' CLIA-certified, CAP-accredited laboratory. Results are provided to you and made available in your online portal. Caris Detect does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results may occur. Caris Detect is intended to complement, not replace, recommended cancer screening tests and other medical evaluations, so it is important that you continue recommended cancer screenings and routine preventive healthcare based on your individual risk factors. Results should be interpreted in conjunction with discussion with your healthcare provider and potential follow-up diagnostic testing. A positive result is not a diagnosis. A negative result does not rule out cancer or mean that an individual will not develop cancer in the future. 2 Reference: Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, Yoshino T, Heath EI, Lou E, Liu SV, Marshall JL, El-Deiry WS, Shields AF, Dietrich MF, Nakamura Y, Fujisawa T, Demetri GD, Barker A, Xiu J, Sacchetti S, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert DD, Oberley M, Radovich M, Sledge GW, Spetzler DB. Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. Sci Rep. 2025 Jul 15;15(1):21173. doi: 10.1038/s41598-025-08986-0. PMID: 40596693; PMCID: PMC12214926. 1f:["$","article",null,{"className":"min-w-0 flex-1 overflow-hidden","aria-label":"One blood test. 55+ cancers.","children":[["$","$L27",null,{"emailId":"105499be-9b5a-4dc7-9af3-4289af547c75"}],["$","$L28",null,{"email":{"id":"105499be-9b5a-4dc7-9af3-4289af547c75","subject":"One blood test. 55+ cancers.","previewText":"everlywell Caris Detect goes deeper than most MCED tests. \n\n \n\n\n\nHow can one test screen for so many cancers?\n\n\n \n\n\n\n It starts with your DNA — and your RNA.\n\n Some multi-cancer","sentAt":"2026-09-19T12:33:15.000Z","classification":"marketing","imageCount":10,"thumbnailUrl":"https://mailspo-ingest.imraan-243.workers.dev/img/inbound/img/03220283654cd1f3a80ed1b83daccc7573237aded41d7b234826b17e03a0c907","emailType":"newsletter","typeConfidence":"guess","typeBasis":"no stronger signal","brand":"$25:props:brands:312","bodyHtml":"$29","textBody":"$2a","bodyFallback":null}}]]}] a:null f:[["$","title","0",{"children":"One blood test. 55+ cancers. by EverlyWell | Mailspo"}],["$","meta","1",{"name":"description","content":"everlywell Caris Detect goes deeper than most MCED tests. \n\n \n\n\n\nHow can one test screen for so man"}],["$","meta","2",{"name":"robots","content":"index, follow"}],["$","link","3",{"rel":"canonical","href":"https://mailspo.com/emails/105499be-9b5a-4dc7-9af3-4289af547c75"}],["$","meta","4",{"property":"og:title","content":"One blood test. 55+ cancers. by EverlyWell | Mailspo"}],["$","meta","5",{"property":"og:description","content":"everlywell Caris Detect goes deeper than most MCED tests. \n\n \n\n\n\nHow can one test screen for so man"}],["$","meta","6",{"property":"og:url","content":"https://mailspo.com/emails/105499be-9b5a-4dc7-9af3-4289af547c75"}],["$","meta","7",{"property":"og:site_name","content":"Mailspo"}],["$","meta","8",{"property":"og:image","content":"https://mailspo-ingest.imraan-243.workers.dev/img/inbound/img/03220283654cd1f3a80ed1b83daccc7573237aded41d7b234826b17e03a0c907"}],["$","meta","9",{"property":"og:image:alt","content":"EverlyWell email creative: One blood test. 55+ cancers."}],["$","meta","10",{"property":"og:type","content":"article"}],["$","meta","11",{"property":"article:published_time","content":"2026-09-19T12:33:15.000Z"}],["$","meta","12",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","13",{"name":"twitter:title","content":"One blood test. 55+ cancers. by EverlyWell | Mailspo"}],["$","meta","14",{"name":"twitter:description","content":"everlywell Caris Detect goes deeper than most MCED tests. \n\n \n\n\n\nHow can one test screen for so man"}],["$","meta","15",{"name":"twitter:image","content":"https://mailspo-ingest.imraan-243.workers.dev/img/inbound/img/03220283654cd1f3a80ed1b83daccc7573237aded41d7b234826b17e03a0c907"}],["$","meta","16",{"name":"twitter:image:alt","content":"EverlyWell email creative: One blood test. 55+ cancers."}],["$","link","17",{"rel":"icon","href":"/favicon.ico?favicon.3lxqohtg4uvbd.ico","sizes":"48x48","type":"image/x-icon"}],["$","$L2b","18",{}]]

Search Mailspo